Market Overview

Cotellic in Combination With Zelboraf Helps People With Specific Advanced Melanoma Live Longer Than With Zelboraf Alone


Genentech, a member of the Roche Group (OTC: RHHBY),
announced Saturday, data from the pivotal coBRIM study, which showed that
Cotellic (cobimetinib) in combination with Zelboraf
(vemurafenib) helped people with BRAF V600E and V600K mutation-positive
unresectable or metastatic melanoma live significantly longer (overall
survival; OS) than with Zelboraf alone. Cotellic plus Zelboraf reduced
the risk of death by 30 percent compared to Zelboraf alone and helped
people live a median of nearly two years (median OS 22.3 months vs. 17.4
months, hazard ratio [HR]=0.70, 95 percent CI: 0.55-0.90, p=0.005). Ongoing
study monitoring did not identify any new safety signals. The final
coBRIM OS results were presented today during the 12th International
Congress of the Society for Melanoma

See full press release

Posted-In: News Press Releases


Related Articles (RHHBY)

View Comments and Join the Discussion!